Study: Pump Inhibitors Can Increase Risk of Death in Lung Cancer Patients

Taiwanese researchers investigate risk factors

Concurrent use of PPIs was associated with lower overall survival in patients with EGFR-mutant non-small cell lung cancer (NSCLC) under first-line gefitinib treatment, according to a recent study conducted in Taiwan.

Using the Taiwan Cancer Registry and Taiwan National Health Insurance databases, researchers performed a nationwide cohort study of patients newly diagnosed with NSCLC between 1997 and 2013. 

They analyzed the association between use of proton pump inhibitors and treatment outcome, defining the coverage ratio of PPIs as duration of PPI treatment in days divided by duration of tyrosine kinase inhibitors (TKIs) in days. Patients who exhibited an overlap of >20% between PPI and TKI usage days were defined as having a high coverage ratio.

Higher PPI coverage ratio significantly decreased overall survival (OS) compared with that of patients with a lower PPI coverage ratio or no PPI treatment in univariate analysis (median OS, 13.5, 16.7, and 21.8 months, respectively, p<0.01) and multivariate analyses (high coverage ratio HR: 1.67; low coverage ratio HR: 1.29)

The entire abstract can be found here.

About The Author

Each year more than 350,000 professionals advance their career with Elite Learning.